BCL2 and glioblastoma: Other combinations of drugs undergoing clinical development for GBM have also been tested with existing compounds such as Navitoclax/ABT-263 (a Bcl-2/Bcl-xL inhibitor) with encouraging in vivo low toxicity and suppression of tumour growth (195).